Abstract
The results of the IFM 95-01 trial comparing MP to Dexamethasone-based regimens were consistent with the fact that the standard MP remained the reference treatment for patients (pts) older than 65 years with multiple myeloma (MM) (
Blood
2003
;102
,147a
Author notes
Corresponding author
2005, The American Society of Hematology
2004
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal